Community Search
WPC Scientific Update 2015
Share |



>Register HERE!

>General Information



>Continuing Education



Download summaries of all SIX sessions

Presented on October 6, 2015

SESSION I- New Therapeutic Strategies for Parkinson's


Learning Objectives: To discuss new innovations in therapy from three angles, including pharmacological, reparative strategies such as DBS, and mechanical bio-engineering; To understand the potential roles and limitations of existing and emerging non-pharmacological approaches to the management of Parkinson's as well as other potential applications.

A. Jon Stoessl (Canada)

New ways to think about pharmacology for Parkinson's

Peter LeWitt (USA)

DBS: New understanding and uses  

Andres Lozano (Canada)

Bioengineering instruments and Parkinson's: a new management tool?  

Sunil Agrawal (USA)

Download Session I Summary


SESSION II- Alpha-nuclein why is it so important to Parkinson's?


Learning Objectives: To understand the importance of the mechanisms responsible for the maintenance of the well being of proteins.

Andrew Singleton (USA)


Roy Alcalay (USA)

LRRK2 as a kinase

Andrew West (USA)

Alpha synuclein, example of aggregation prone factors

Tiago Outeiro (Germany)

Download Session II Summary



Presented on October 7, 2015


SESSION III- Emerging Targets in Parkinson's


Learning Objectives: To understand current unmet needs and appreciate the obstacles that must be overcome in order to develop a neuroprotective therapy; To understand how to identify targets to alleviate the symptoms unresponsive to dopaminergic treatment or the side effects of dopaminergic treatments.

Etienne Hirsch (France)

New targets covering side effects of PD treatments

Erwan Bezard (France)  

Ongoing pursuit of neuroprotective therapies

Tom Foltynie (UK)

Non-motor issues: different ways to think about targets

K. Ray Chaudhuri (UK)

Download Session III Summary


SESSION IV- Exercise: What do we know about how it impacts Parkinson's?


Learning Objectives: To explain how exercise impacts a Parkinson patient's health and well being from three perspectives, including neurophysiological impact, clinical impact, and rehabilitation impact.

Fay Horak (USA)

What happens in the brain when exercise happens?

Richard Smeyne (USA)

Clinical dimension of exercise and PD

Giselle Petzinger (USA)

Where does exercise meet rehabilitation & why?

Gammon Earhart (USA)

Download Session IV Summary


Presented on October 8, 2015


SESSION V- Cognitive Challenges and Parkinson's: What can really be done?


Learning Objectives: To describe the clinical features, syndromes and proposed mechanisms of cognitive dysfunction across the spectrum of Parkinson's disease; To describe the available and emerging treatments for cognitive impairment associated with Parkinson's.

David Burn (UK)

Cognition across the life span: the cause and progression

Dag Aarsland (Sweden)

Mild cognitive impairment in Parkinson's- what does it mean?

Alexander Troster (USA)

Emerging therapies for cognition: what can we expect?

Jennifer Goldman (USA)

Download Session V Summary


SESSION VI- Gene & Stem Cell Therapy: Can these really impact Parkinson's?


Learning Objectives: To appreciate the experimental development and current applications of cell and gene based therapies.

Jeffrey Kordower (USA)

Viral vectors & overview of cellular implanting

Krystof Bankiewicz (USA)

Antisense oligonucleotide: a form of non-viral based therapy

Marie-Francoise Chesselet (USA)

Stem cells

Roger Barker (UK)

Download Session VI Summary

Register NOW!

Membership Management Software Powered by YourMembership  ::  Legal